Grants for Independent school districts - Federal

The U.S. Standard Grants Program is a competitive, matching grant program that supports public-private partnerships carrying out projects in the United States that further the goals of the North American Wetlands Conservation Act. The program promotes partnerships projects that must involve a) only long-term protection, restoration, enhancement and/or establishment of wetland and associated upland habitats to benefit diversity of wetland ecosystems and b) maintaining an abundance of waterfowl (ducks, geese, and swans) and other populations of wetlands-associated migratory birds consistent with the objectives of the North American Waterfowl Management Plan, U.S. Shorebird Conservation Plan, Waterbird Conservation Plan for the Americas, and Partners in Flight Bird Conservation Plan. The program requires a 1:1 non-federal match and research funding is ineligible. This program supports the Department of Interior and U.S. Fish and Wildlife Service mission of protecting and managing the nation natural resources by collaborating with partners and stakeholders to conserve land and water and to expand outdoor recreation and access. Also, this program contributes to efforts to reduce climate pollution, support climate resilience, support land conservation and biodiversity efforts and leverage partnerships.

This funding opportunity supports U.S. institutions in providing research education and mentorship for recent graduates from diverse backgrounds to prepare them for neuroscience doctoral programs.

The Administration for Children and Families (ACF) plans to solicit applications for Child Care Policy Research Partnerships (CCPRP). These five-year cooperative agreements will support partnerships between Child Care and Development Fund (CCDF) Lead Agencies in states, territories, or tribes and research partner organizations with demonstrated research capacity to develop rigorous investigations of child care subsidy policies and practices. Sponsored projects will inform local and federal understanding about the efficacy of child care subsidy policies and practices to increase low-income families access to quality child care. To ensure that the funded work is timely and relevant to the current child care context, the CCDF Lead Agency and their research partner organization(s) must collaborate actively throughout all phases of the project and are encouraged to engage other local and state child care entities, as appropriate. This iteration of the CCPRP awards will prioritize research projects implementing rigorous, policy-relevant evaluations that will test whether quality improvement initiatives in states, territories, or tribes implemented through the CCDF quality set-aside increase families access to quality child care, especially access for: children in underserved areas, infants and toddlers, children with disabilities, and children in nontraditional-hour care. Sponsored projects will be expected to participate in a consortium that will meet and communicate regularly to identify opportunities for coordination, such as common data elements and research methods, and to develop collective expertise and resources for the field. The consortiums collaboration will support research capacity and learning within individual projects and across recipients. For further information about prior awards made for CCPRP, see https://www.acf.hhs.gov/opre/project/child-care-policy-research-partnerships-1995-2023.

The IIJA/IRA Bureau of Land Management National Operations Center (NOC) Forest and Woodlands Resource Management grant aims to fund projects that enhance wildfire resilience, promote sustainable forest management and bioenergy through biomass utilization, with a focus on restoring forest and woodland ecosystems, supporting sustainable wood products, reforestation, and salvaging dead or dying timber, offering between $25,000 to $500,000 per project, with a total fund of $800,000 available, and applications are due by September 30, 2024.

This funding opportunity provides financial support for multidisciplinary research teams to investigate tuberculosis and its interactions with the host, aiming to improve understanding and treatment of the disease.

This funding opportunity provides financial support for innovative research projects that explore the complex relationship between adolescent social media use and mental health, particularly focusing on underserved youth populations.

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs.Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants.The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516.FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

This funding opportunity supports community projects in New England that aim to reduce environmental risks and improve public health, particularly for vulnerable populations such as children, the elderly, and those in environmental justice areas.

This funding opportunity supports collaborations between academic institutions and industry to develop innovative technologies that improve disease diagnosis, treatment, and management, particularly for underserved populations.

This funding opportunity supports research into how certain diabetes medications may influence cancer risk, encouraging studies that explore the underlying biological mechanisms involved.

This grant provides funding for innovative research using invasive brain recording and stimulation techniques in humans to improve understanding of the neural circuits involved in mental health disorders.

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. NINDS is committed to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. See the Notice of NIH

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

The Administration for Children and Families (ACF) is funding a cooperative agreement to sponsor the Child Development Research Fellowship that gives child development professionals from across the national academic research community the opportunity to experience policy research relevant to programs serving low-income children and families. This award is for an organization to lead the Child Development Research Fellowship Program. The organization must be a Professional Membership Organization for researchers who can support the Child Development Research Fellowship Program. A Professional Membership Organization aims to support individuals professionally and aid them in progressing within their career/profession. The goal of the fellowship program is to expose researchers to policy environments, particularly at the federal level, whereby they gain skills and expertise for policy-relevant research. The program is intended to stimulate the fellows knowledge of child development research and evaluation, particularly regarding services for low-income children and families, and to inform their process of developing long-term, policy-relevant research and evaluation agendas. The public will benefit from the increased availability of researchers highly skilled and experienced in policy and program relevant research and evaluation. Fellows will engage on a full-time basis for a period of 1 year (with a possible second or third year at the discretion of the award recipient and depending on funding availability). Fellows will be exposed to the broader child development policy environment, particularly at the federal level, and to the policy research community through activities organized and conducted by the award recipient. Fellows will learn extensively about ACF and our programs that serve young children and their families. The cooperative agreement will require active partnership between the successful applicant and Office of Planning, Research and Evaluation (OPRE).For more information about OPRE, see http://www.acf.hhs.gov/opre . Please subscribe to this forecast at grants.gov to receive notification of any updates.

The Office of Refugee Resettlement (ORR), within the Administration for Children and Families (ACF), announces the availability of funds for the National Refugee Leadership and Lived Experience Council (NRLLEC) Program. The NRLLEC is a new program funded by the Office of Refugee Resettlement (ORR) that designs, implements, evaluates, and promotes national-level councils consisting of refugees and other ORR-eligible populations who have resettled into communities throughout the United States within the last five years. The NRLLEC Program will facilitate a National Young Adult Leadership Council comprised of members ages 18 to 24 every year for three years, as well as two additional councils with thematic focus to be determined in consultation with ORR. The NRLLEC Program will design, implement, evaluate, and promote five councils during the three-year project period. The programs primary goal is to positively impact the lives of council members and their refugee and larger communities by building council members capacity to serve as leaders. In addition, ORR recognizes that its engagement with these groups will enhance its ability to gather information from individual members firsthand about their lived experiences integrating into the United States. This will help inform ORR and its recipient network about how to best meet refugee needs through enhancing or changing ORR guidance, programming, and future councils. The NRLLEC Program will foster inclusivity, with council members attuned to the diversity, demographics, needs, and viewpoints of ORRs eligible population (https://www.acf.hhs.gov/orr/programs/refugees/factsheets). The NRLLEC Program will not seek consensus advice from council members.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.